AU2017238181B2 - Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer - Google Patents

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer Download PDF

Info

Publication number
AU2017238181B2
AU2017238181B2 AU2017238181A AU2017238181A AU2017238181B2 AU 2017238181 B2 AU2017238181 B2 AU 2017238181B2 AU 2017238181 A AU2017238181 A AU 2017238181A AU 2017238181 A AU2017238181 A AU 2017238181A AU 2017238181 B2 AU2017238181 B2 AU 2017238181B2
Authority
AU
Australia
Prior art keywords
group
cell
tumor
compound
psma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017238181A
Other languages
English (en)
Other versions
AU2017238181A1 (en
Inventor
Martin G. Pomper
Sangeeta Ray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2017238181A1 publication Critical patent/AU2017238181A1/en
Application granted granted Critical
Publication of AU2017238181B2 publication Critical patent/AU2017238181B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2017238181A 2016-03-22 2017-03-22 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer Active AU2017238181B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311697P 2016-03-22 2016-03-22
US62/311,697 2016-03-22
PCT/US2017/023508 WO2017165473A1 (en) 2016-03-22 2017-03-22 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Publications (2)

Publication Number Publication Date
AU2017238181A1 AU2017238181A1 (en) 2018-10-18
AU2017238181B2 true AU2017238181B2 (en) 2021-05-27

Family

ID=59899817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017238181A Active AU2017238181B2 (en) 2016-03-22 2017-03-22 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Country Status (27)

Country Link
US (3) US11458213B2 (enExample)
EP (3) EP4385981A1 (enExample)
JP (4) JP7073270B2 (enExample)
KR (4) KR20250057132A (enExample)
CN (3) CN114716387B (enExample)
AU (1) AU2017238181B2 (enExample)
BR (1) BR112018069507A2 (enExample)
CA (1) CA3018709A1 (enExample)
CL (1) CL2018002683A1 (enExample)
CY (1) CY1124487T1 (enExample)
DK (2) DK3433238T3 (enExample)
ES (2) ES2877572T3 (enExample)
FI (1) FI3925952T3 (enExample)
HR (2) HRP20211386T1 (enExample)
HU (2) HUE065327T2 (enExample)
LT (2) LT3925952T (enExample)
MX (1) MX384823B (enExample)
PH (1) PH12018502048A1 (enExample)
PL (2) PL3925952T3 (enExample)
PT (2) PT3433238T (enExample)
RS (2) RS62274B1 (enExample)
RU (2) RU2021115958A (enExample)
SA (1) SA518400103B1 (enExample)
SI (2) SI3433238T1 (enExample)
TR (1) TR201813644T1 (enExample)
WO (1) WO2017165473A1 (enExample)
ZA (1) ZA201806389B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392700B (es) 2016-08-10 2025-03-11 Cancer Targeted Tech Llc Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
CN109982998A (zh) * 2016-11-23 2019-07-05 癌靶技术有限责任公司 白蛋白结合psma抑制剂
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
US11478558B2 (en) 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
EP3494999A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
DK3723815T3 (da) * 2017-12-11 2022-07-11 Univ Muenchen Tech PSMA ligander til billeddannelse og endoradioterapi
EP3494998A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
DK3498308T3 (da) * 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid
PH12020551205A1 (en) * 2018-02-06 2021-04-19 Univ Heidelberg Fap inhibitors
WO2019157037A1 (en) * 2018-02-06 2019-08-15 The Johns Hopkins University Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
KR102156385B1 (ko) * 2018-03-30 2020-09-15 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
EP4556031A3 (en) * 2018-04-27 2025-06-25 University of Iowa Research Foundation Compositions for chelating metals at low temperatures
CN121534209A (zh) * 2018-09-28 2026-02-17 海德堡大学 前列腺特异性膜抗原(psma)的标记抑制剂，其作为显像剂和药剂用于治疗表达psma的癌症的用途
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
KR102403970B1 (ko) * 2018-12-27 2022-05-31 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
KR20220044496A (ko) * 2019-07-02 2022-04-08 어드밴스드 액셀러레이터 어플리케이션즈 (이태리) 에스알엘 전립선 특이적 막 항원(psma) 리간드 및 이의 용도
CN114096526A (zh) * 2019-07-02 2022-02-25 诺华股份有限公司 前列腺特异性膜抗原（psma）配体及其用途
RU2730507C1 (ru) * 2019-08-27 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе
US20230097381A1 (en) * 2020-04-24 2023-03-30 Radiomedix, Inc. Composition, kit and method for diagnosis and treatment of prostate cancer
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
WO2022108992A1 (en) * 2020-11-17 2022-05-27 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
ES3053944T3 (en) * 2020-11-19 2026-01-28 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.
EP4355376A4 (en) * 2021-06-17 2025-10-15 Mayo Found Medical Education & Res METHODS AND MATERIALS FOR COMBINING BIOLOGICALS WITH MULTIPLE CHELATORS
KR20230050552A (ko) * 2021-10-07 2023-04-17 (주)퓨쳐켐 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
KR20250127126A (ko) * 2022-12-21 2025-08-26 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료
EP4746926A2 (en) 2023-07-21 2026-05-27 Novartis AG Psma-targeting radioligand treatment regimen
WO2026124661A1 (zh) * 2024-12-13 2026-06-18 长春金赛药业有限责任公司 前列腺特异性膜抗原抑制剂、其放射性核素标记物及其用途
WO2026159621A1 (en) 2025-01-23 2026-07-30 Novartis Ag Treatment regimen using psma-binding radioligands in combination with androgen receptor pathway inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034494A1 (en) * 2011-08-05 2013-02-07 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2017116994A1 (en) * 2015-12-31 2017-07-06 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002529A2 (en) * 2007-06-26 2008-12-31 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
AU2009322167B2 (en) * 2008-12-05 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
EP4420730A3 (en) 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
EP2785712B1 (en) * 2011-11-30 2019-05-01 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
HUE035739T2 (en) * 2013-01-14 2018-05-28 Molecular Insight Pharm Inc Triazine-based radiopharmaceuticals and radiological imaging agents
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
ES2743482T3 (es) 2014-05-06 2020-02-19 Univ Johns Hopkins Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia
US10112974B2 (en) * 2014-08-24 2018-10-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer
WO2016065435A2 (en) * 2014-10-30 2016-05-06 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US11520472B2 (en) * 2015-09-24 2022-12-06 Mitutoyo Corporation Inspection program editing environment including integrated alignment program planning and editing features

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034494A1 (en) * 2011-08-05 2013-02-07 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2017116994A1 (en) * 2015-12-31 2017-07-06 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EDER, M. et al., "68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging", Bioconjugate Chemistry, (2012), vol. 23, pages 688 - 697 *
M BENESOVA ET AL, "Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, (2016), v 59, p1761-75 *

Also Published As

Publication number Publication date
KR20180134918A (ko) 2018-12-19
EP4385981A1 (en) 2024-06-19
SI3925952T1 (sl) 2024-03-29
PL3433238T3 (pl) 2021-12-13
JP2022116028A (ja) 2022-08-09
CN114716387A (zh) 2022-07-08
JP2026021351A (ja) 2026-02-10
MX384823B (es) 2025-03-14
JP2019519467A (ja) 2019-07-11
TR201813644T1 (tr) 2018-11-21
KR102396307B1 (ko) 2022-05-09
MX2018011519A (es) 2019-01-28
HUE055607T2 (hu) 2021-12-28
EP3433238B1 (en) 2021-06-16
SA518400103B1 (ar) 2022-03-20
KR20230147751A (ko) 2023-10-23
PL3925952T3 (pl) 2024-04-22
CY1124487T1 (el) 2022-07-22
EP3433238A1 (en) 2019-01-30
CN109311827A (zh) 2019-02-05
JP7073270B2 (ja) 2022-05-23
HUE065327T2 (hu) 2024-05-28
US20250195700A1 (en) 2025-06-19
EP3925952A1 (en) 2021-12-22
US20200155713A1 (en) 2020-05-21
RU2018133693A3 (enExample) 2020-04-22
ES2972148T3 (es) 2024-06-11
NZ786380A (en) 2025-05-02
RS62274B1 (sr) 2021-09-30
PT3433238T (pt) 2021-07-28
RS65188B1 (sr) 2024-03-29
RU2018133693A (ru) 2020-04-22
PT3925952T (pt) 2023-12-13
US20230015736A1 (en) 2023-01-19
DK3433238T3 (da) 2021-09-06
RU2749399C2 (ru) 2021-06-09
FI3925952T3 (fi) 2024-02-13
HRP20240215T1 (hr) 2024-04-26
US11458213B2 (en) 2022-10-04
WO2017165473A1 (en) 2017-09-28
ZA201806389B (en) 2024-01-31
SI3433238T1 (sl) 2021-11-30
LT3925952T (lt) 2024-01-25
LT3433238T (lt) 2021-09-27
PH12018502048A1 (en) 2019-07-01
JP2024050608A (ja) 2024-04-10
KR20250057132A (ko) 2025-04-28
ES2877572T3 (es) 2021-11-17
DK3925952T3 (da) 2024-02-05
CA3018709A1 (en) 2017-09-28
KR20220063298A (ko) 2022-05-17
EP3433238A4 (en) 2019-09-11
NZ746701A (en) 2024-12-20
EP3925952B1 (en) 2023-11-29
CN120172884A (zh) 2025-06-20
HRP20211386T1 (hr) 2021-12-10
RU2021115958A (ru) 2021-07-12
CN109311827B (zh) 2022-04-12
CN114716387B (zh) 2025-04-01
BR112018069507A2 (pt) 2019-01-29
CL2018002683A1 (es) 2019-04-22
AU2017238181A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
US20250195700A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
AU2019217838B2 (en) PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
AU2017263630B2 (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof
US10232058B2 (en) Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
WO2018222778A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
US20210338846A1 (en) Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
WO2017070482A2 (en) Psma targeted radiohalogenated ureas for cancer radiotherapy
HK1259764B (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
BR122025009780A2 (pt) Compostos, método para tratar uma ou mais células ou tumores que expressam psma in vitro ou ex vivo que utiliza os ditos compostos e uso dos mesmos para tratar tumores ou células que expressam psma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)